genedrive
plc
("genedrive" or the
"Company")
Notification and public
disclosure of transactions by persons discharging
managerial responsibilities
and persons closely associated with them
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company, announces that it has
granted share options ("Options") to members of its senior
management team to acquire a total of 8,900,000 new ordinary shares
of 1.5p each ("Ordinary Shares") in the Company under the Company's
Share Option Scheme.
The Options have been granted with
an exercise price equal to the close price on 19 December 2024,
being the day before the grant and vest after a period of three
years, subject to certain performance criteria being met through
achieving revenue targets, achieving cash targets and completing
certain strategic projects in the year ending June 2026. The
Options are exercisable over the period of 10 years from the date
of grant.
The information set out below is
provided in accordance with the requirements of Article 19(3) of
the EU Market Abuse Regulation No 596/2014.
|
1.
|
Details of the person
discharging managerial responsibilities / person closely
associated
|
|
a.
|
Name
|
Gino Miele Chief Executive Officer
Russell Shaw
Chief Financial Officer
Patrick Breen
Chief Commercial Officer
Jonathan Barber
Operations Director
Shaun Ainsworth
Assay Development Director
Grzegorz Zysko
Engineering Director
Caroline Alexander
Director QA/RA
|
|
2.
|
Reason for the
notification
|
|
a.
|
Position/status
|
See box 1a.
above
|
|
a.
|
Initial notification
/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer,
emission allowance market participant, auction platform, auctioneer
or auction monitor
|
|
a.
|
Name
|
genedrive plc
|
|
b.
|
LEI
|
213800ZYODIRZ87Y4K14
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a.
|
Description of the
Financial instrument, type
of
instrument
Identification code
|
Options over ordinary shares of 1.5
pence each
GB00B1VKB244
|
|
b.
|
Nature of the transaction
|
Grant of options pursuant to, and in accordance with, the
terms of the Company's Share Option Scheme dated 29 November
2017
|
|
c.
|
Price(s) and volume(s)
|
|
|
Option
price(s)
|
Volume(s)
|
|
Gino Miele
|
2.1p
|
3,500,000
|
|
Russell Shaw
|
2.1p
|
3,500,000
|
|
Patrick Breen
|
2.1p
|
600,000
|
|
Jonathan Barber
|
2.1p
|
400,000
|
|
Shaun Ainsworth
|
2.1p
|
400,000
|
|
Grzegorz Zysko
|
2.1p
|
400,000
|
|
Caroline Alexander
|
2.1p
|
100,000
|
|
|
d.
|
Aggregated information
Aggregated volume
Price
|
N/A
|
|
e.
|
Date of the transaction
|
2024-12-20
|
|
f.
|
Place of the transaction
|
Outside a
trading venue - shares to be admitted to
AIM market of London Stock Exchange plc on exercise of
options
|
For further details please
contact:
|
genedrive plc
|
+44 (0)161
989 0245
|
|
Gino Miele: CEO / Russ Shaw:
CFO
|
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
|
James Steel / Patrick
Birkholm
|
|
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About
genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic testing
company developing and commercialising a low cost, rapid, versatile
and simple to use point of need pharmacogenetic platform for the
diagnosis of genetic variants. This helps clinicians to quickly
access key genetic information that will aid them make the right
choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care
healthcare paradigms. Based in the UK, the Company is at the
forefront of Point of Care pharmacogenetic testing in emergency
healthcare. Pharmacogenetics informs on how your individual
genetics impact a medicines ability to work for you. Therefore, by
using pharmacogenetics, medicine choices can be personalised, made
safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19
ID Kit, both developed and validated in collaboration with NHS
partners and deployed on its point of care thermocycler platform.
Both tests are single-use disposable cartridges which are ambient
temperature stable, circumventing the requirement for cold chain
logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a
worlds-first and allows clinicians to make a decision on antibiotic
use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially
otherwise encountered and with no negative impact on the patient
care pathway. Its CYP2C19 ID Kit which has no comparably positioned
competitor currently allows clinicians to make a decision on the
use of Clopidogrel in stroke patients in 70 minutes, ensuring that
patients who are unlikely to benefit from or suffer adverse effects
from Clopidogrel receive an alternative antiplatelet therapeutic in
a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care
Clinical Excellence ("NICE") and have been recommended for use in
the UK NHS.
The Company has a clear commercial strategy
focused on accelerating growth through maximising in-market sales,
geographic and portfolio expansion and strategic M&A, and
operates out of its facilities in Manchester.